Literature DB >> 9256197

CD4+ T cells are able to reject class I disparate allografts.

T Sawada1, Y Wu, D H Sachs, J Iacomini.   

Abstract

The ability of CD4+ T cells to reject class I mismatched skin allografts remains controversial. In this study, we compare the ability of CD4+ T cells to reject class I disparate skin grafts differing by either a single class I allelic disparity or only 3 amino acids encoded by the H-2K locus. We demonstrate that skin grafts across a full H-2K allelic disparity, but not across a disparity of only three amino acids are efficiently rejected by CD4+ T cells. This observation is consistent with the possibility that peptides derived from allogeneic class I molecules generated through the major histocompatibility complex (MHC) class II antigen processing pathway can be recognized by host CD4 T cells and lead to rejection of class I mismatched skin grafts. The availability of peptides derived from allogeneic MHC class I molecules for presentation by host MHC class II may determine the efficiency of rejection of class I mismatched allografts by CD4+ T cells. Thus, class I mismatched allografts can be rejected by CD4+ T cells provided that host and donor MHC class I molecules are sufficiently disparate to activate CD4+ effectors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9256197     DOI: 10.1097/00007890-199707270-00027

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  Induction of transplantation tolerance by combining non-myeloablative conditioning with delivery of alloantigen by T cells.

Authors:  Chaorui Tian; Xueli Yuan; Jessamyn Bagley; Bruce R Blazar; Mohamed H Sayegh; John Iacomini
Journal:  Clin Immunol       Date:  2008-02-15       Impact factor: 3.969

2.  γδ T cells augment rejection of skin grafts by enhancing cross-priming of CD8 T cells to skin-derived antigen.

Authors:  Azad Rahimpour; Stephen R Mattarollo; Michelle Yong; Graham R Leggatt; Raymond J Steptoe; Ian H Frazer
Journal:  J Invest Dermatol       Date:  2012-02-23       Impact factor: 8.551

3.  Tolerance to MHC class II disparate allografts through genetic modification of bone marrow.

Authors:  P T Jindra; S Tripathi; C Tian; J Iacomini; J Bagley
Journal:  Gene Ther       Date:  2012-07-26       Impact factor: 5.250

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.